Jafron Biomedical Co.Ltd(300529) 4 issued the 2021 annual report on April 11. During the reporting period, the company achieved an operating revenue of 2.675 billion yuan, a year-on-year increase of 37.15%; The net profit attributable to shareholders of listed companies was 1.197 billion yuan, a year-on-year increase of 36.74%; The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 1.137 billion yuan, a year-on-year increase of 35.17%, and the net cash flow from operating activities was 1.249 billion yuan, a year-on-year increase of 30.49%.
The company’s products in the field of Nephrology have covered more than 6000 large and medium-sized hospitals in China. In 2021, all kinds of perfusion devices in nephrology achieved a total revenue of 17240211 million yuan, a year-on-year increase of 27.70%, accounting for 64.55% of the company’s main business income; Hemodialysis powder and liquid achieved a revenue of 541667 million yuan, a year-on-year increase of 79.12%.
In July 2021, the research on health economics of Jianfan ha resin hemoperfusion was officially published in annals of translational medicine; In October, Jianfan ha resin hemoperfusion device was listed in the Shanghai expert consensus on the clinical application of hemoperfusion in maintenance hemodialysis patients; In November, the National Health Commission officially issued the standard operating procedures for blood purification (version 2021) (SOP), which pointed out that “once a week, ha resin hemoperfusion and hemodialysis can be treated in series for 2h, which can significantly improve the serum iPTH and blood pressure of maintenance hemodialysis patients β 2. Improve the clearance rate of microglobulin and improve itching symptoms. “Ha resin hemoperfusion device is a unique product of the company. The above three evidence-based medical evidence will have a far-reaching impact on the company’s product coverage and treatment frequency.
The company’s products in the field of liver diseases have covered more than 1500 hospitals, with a total revenue of 310.49 million yuan, a year-on-year increase of 69.19%, accounting for 11.62% of the company’s main business income. The company’s long-distance project, one city and one center project and freshman plan were promoted in an orderly manner.
The company’s products in the field of critical illness have covered more than 1000 hospitals. Ha330 and ha380 in the Chinese market have achieved a revenue of 173043 million yuan, a year-on-year increase of 63.89%, accounting for 6.48% of the company’s main business revenue; Among them, the sales revenue of ha380 was 656758 million yuan, a year-on-year increase of 532.1%.
In 2021, the company achieved product sales in more than 80 countries, and the international market achieved a revenue of 127802 million yuan, a year-on-year increase of 137.99%, accounting for 4.78% of the company’s main business revenue.
In 2021, the company invested 173771400 yuan in R & D, with a year-on-year increase of 115.17%, accounting for 6.5% of the company’s revenue.
